Natural Beauty Bio-Technology stock came into today on a soft footing, with the share price down about 3% over the past week and about 4% over the past month. Yet the latest half year report is less about short term trading and more about a deepening profitability problem. The headline is the earnings squeeze. For H1 2026 the company reported a basic loss per share of HK$0.028586 and a loss from continuing operations of HK$57.463 million on HK$523.384 million of trailing twelve month revenue. The market now has to weigh that pressure against any hopes for a longer term recovery.

Is Natural Beauty Bio-Technology now pricing in a turnaround that its loss profile does not yet support, or is the market already discounting deeper trouble? Compare current P/S and earnings trends against peers in the valuation analysis for Natural Beauty Bio-Technology.

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025): HK$523.384 million compared with HK$461.406 million (reflecting higher reported revenue)
• Net Loss from Continuing Operations (H1 2026 vs. H1 2025): HK$57.463 million loss compared with HK$62.231 million loss (loss narrowed)
• Basic EPS (H1 2026 vs. H1 2025): HK$0.028586 loss per share compared with HK$0.031082 loss per share (loss per share narrowed)
• Net Income Excluding Extra Items (H1 2026 vs. H2 2025): HK$57.48 million loss compared with HK$10.581 million profit (shifted from profit to loss over the last two half-year periods)

Prefer clean charts over wading through another wall of earnings figures and footnotes? See the full visual breakdown of Natural Beauty Bio-Technology, with a clear focus on its profitability trend, in the company report for Natural Beauty Bio-Technology.

Natural Beauty Bull Case Hangs On Revenue Resilience

For anyone leaning positive on Natural Beauty Bio-Technology, the latest figures offer one clear supporting thread. Revenue of HK$523.384 million over the trailing twelve months sits above the H1 2025 level of HK$461.406 million, which supports the view of an established brand that can still bring customers through the door across products and services. The net loss from continuing operations narrowed slightly compared with H1 2025, which at least points to some pressure easing even as the business continues to work through a loss making phase.

Profitability Drag Keeps Natural Beauty Bear Case Alive

On the risk side, Natural Beauty Bio-Technology still faces a firm profitability hurdle. The company reported a loss from continuing operations of HK$57.463 million and a basic loss per share of HK$0.028586 for H1 2026. Net income excluding extra items shifted from a HK$10.581 million profit in H2 2025 to a HK$57.48 million loss. Recent share price performance, with the stock down around 3% over 7 days and about 4% over 30 and 90 days, is consistent with investors focusing on this earnings squeeze.

After several years of declining earnings and pressure on operating cash flow coverage, it is worth asking whether these losses hint at deeper structural issues. Review our independent risk analysis for Natural Beauty Bio-Technology which shows 2 important warning signs

Stay Ahead Of Your Next Move

If the recent losses at Natural Beauty Bio-Technology have you weighing whether this is pressure or potential, register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and spot a more comfortable entry point. Once you decide to take a position, use the Portfolio Command Center to keep your holdings organised and cut through market noise with focused alerts. For a broader view on sentiment around Natural Beauty Bio-Technology, the Community connects you with investor perspectives and debate in one place. That way you can surface hidden catalysts or risks earlier and stay a step ahead of the market.

Seeking Alternatives Beyond Natural Beauty Bio-Technology?

Fresh ideas move first. Stocks with early momentum can fly before most investors even notice. Scan these focused lists before the crowd, while it matters, and get in early.

• Spot sturdy businesses with room to grow by reviewing a curated list of solid balance sheet and fundamentals stocks (422 results) that highlights companies balancing resilience with disciplined fundamentals.
• Ride structural trends with less drama by checking 299 resilient stocks with low risk scores that have been filtered for steadier risk profiles and more consistent performance drivers.
• Catch potential breakout leaders in automation by scanning 36 robotics and automation stocks aligned with long term demand for efficiency and industrial productivity gains.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.